Novadip Raises €10.4 Million ($11.98 Million) To Complete NVD003 Phase 3 Trial
By Amit Chowdhry ● Today at 10:59 AM
Novadip Biosciences has raised €10.4 million ($11.98 million) in convertible financing to advance its lead regenerative medicine program NVD003 through pivotal Phase 3 development and prepare for a U.S. regulatory submission. The financing was led by U.S.-based New Science Ventures, with participation from existing investors Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq and Invest.BW.